The difficulty of obtaining an antimalarial vaccine along traditional lines, because of the highly adaptive character of the malaria parasite, prompts a ceaseless need for new drugs. To this end, marine organisms have been explored recently, as reviewed in this article within the perspective of clinically available antimalarial drugs and promising candidates. Most promising are tetrahydropyrrolo[1,2-alpha]pyrimidinium, bis-indole, and C(11)-N(5) alkaloids from sponges; pyridoacridone and decahydroquinoline alkaloids from ascidians; and pyrrole alkaloids from fungi, as well as polycyclic polyketides, norditerpene, and polyketide endoperoxides, terpene isonitriles, and, particularly, mixed-biogenesis alpha-galactosyl ceramides from sponges. The first and the latter classes of agents best fulfill the requirements for combinatorial synthesis in providing a wide variety of compounds for high-throughput screening and toxicity tests. These results came largely from nonprofit organizations, a trend that we foresee will continue. However, partnership with the pharmaceutical industry was and is needed to bring candidate drugs to the clinic. In any event, success will not be achieved without political plans to make the results of technology easily available to poor populations.